Shilpa Biologicals Private Limited (SBPL) is a pioneering biopharmaceutical company dedicated to developing and manufacturing high-quality, affordable biologics for patients worldwide. With state-of-the-art research and development facilities located in Dharwad, Karnataka, India, SBPL specialises in creating curative therapies in the fields of immunology and haematology.

Established with a vision to make superior medicines accessible at the most affordable prices, SBPL has positioned itself as a leader in the biopharmaceutical industry. The company boasts a cutting-edge team of scientists and committed professionals who focus on developing innovative therapies. SBPL's product pipeline is centred on immunology and haematology sectors, aiming to provide cost-effective treatments to patients globally. The company's services are underpinned by strong scientific expertise and a commitment to contributing to significant scientific advancements worldwide.

Key Products and Services:

Biosimilars: SBPL has developed a range of biosimilars targeting various therapeutic areas, including immunology, oncology, and ophthalmology. Notably, the company has successfully completed human clinical studies for its Adalimumab biosimilar, demonstrating its commitment to expanding access to essential biologics.

Contract Development and Manufacturing Organisation (CDMO) Services: SBPL offers customised CDMO services to global clients, encompassing clone development, process development, analytical and microbiological testing, and large-scale manufacturing. The company's capabilities include working with both microbial and mammalian host systems, ensuring flexibility and expertise in various production processes.

Manufacturing: Equipped with advanced facilities, SBPL provides mammalian and microbial drug substance manufacturing, as well as drug product manufacturing. The company utilises single-use bioreactors and stainless-steel fermenters, adhering to stringent quality standards to ensure the safety and efficacy of its products.

Research and Development: SBPL invests heavily in R&D to drive innovation in biologics. The company has developed unique perfusion processes using Alternative Tangential Flow (ATF) technology, optimising the recovery of fusion proteins while preserving their biological properties.

SBPL's leadership team is spearheaded by Chief Executive Officer Dr. Sridevi Khambhampaty, who brings over 22 years of experience in the biopharmaceutical and biotechnology sectors. Her extensive expertise in developing innovative products, including proteins and monoclonal antibodies, is instrumental in guiding the company's strategic direction.

SBPL maintains an integrated quality system that meets regulatory requirements to ensure the quality, safety, and efficacy of its products. Regular inspections of facilities and product approvals testify to the company's unwavering commitment to quality.
SHILPABIO

SBPL has established strategic partnerships to enhance its product offerings and expand its reach. For instance, the company has entered into a licensing and supply agreement with Sun Pharmaceuticals to market and distribute its Adalimumab biosimilar across India, aiming to improve patient access to essential biologics.

Through its relentless pursuit of excellence and innovation, Shilpa Biologicals Private Limited continues to make significant strides in the biopharmaceutical industry, striving to improve global healthcare outcomes by providing affordable and high-quality therapeutic solutions.